Related Experiment Video
Updated: Oct 25, 2025
08:46
Cell-Free Production of Proteoliposomes for Functional Analysis and Antibody Development Targeting Membrane Proteins
Published on: September 22, 2020
4.1K
A simple, fast, and orientation-controllable technology for preparing antibody-modified liposomes
Yuma Hirata1, Riho Tashima1, Naoto Mitsuhashi2
1Faculty of Pharmaceutical Science, Tokushima University, Shomachi-1-78-1, Tokushima, Tokushima 770-8505, Japan.
International Journal of Pharmaceutics
|August 5, 2021
Summary
Researchers developed a fast, simple method using staphylococcal protein A (DPACK) to attach antibodies to liposomes for targeted cancer therapy. This antibody-liposome technology enhances nanoparticle delivery to cancer cells, improving drug delivery efficiency.
Area of Science:
- Biotechnology
- Nanotechnology
- Immunology
Background:
- Antibody modification of nanoparticles enhances targeted delivery to specific cells.
- Current methods for antibody conjugation are complex, inefficient, and lack orientation control.
Purpose of the Study:
- To develop a simple, fast, effective, and orientation-controllable method for antibody conjugation to liposomes.
- To utilize staphylococcal protein A for antibody-liposome complex formation.
Main Methods:
- Engineered a staphylococcal protein A derivative (DPACK) with a lysine cluster for electrostatic binding to anionic liposomes.
- Developed a two-step process: DPACK-liposome interaction followed by antibody-DPACK-liposome interaction.
- Validated binding efficiencies of DPACK to liposomes (75%) and IgG to DPACK-liposomes (72-84%).
Main Results:
- Successfully prepared antibody-modified liposomes in 35 minutes.
- Demonstrated significantly higher uptake of anti-EGFR antibody-modified liposomes by EGFR-expressing cancer cells compared to unmodified liposomes.
- Observed accumulation and colocalization of antibody-modified liposomes within tumors.
Conclusions:
- The DPACK-based technology provides a simple, rapid, and orientation-controlled method for preparing antibody-modified liposomes.
- This approach is highly effective for active targeting drug delivery, particularly in cancer therapy.
- The technology shows promise for improving the efficacy of nanoparticle-based drug delivery systems.
